Literature DB >> 6403664

Inactivation of hepatitis B virus by three methods: treatment with pepsin, urea, or formalin.

E Tabor, E Buynak, L A Smallwood, P Snoy, M Hilleman, R J Gerety.   

Abstract

Dilutions of human sera containing between 10(3) and 10(5) chimpanzee infectious doses of hepatitis B virus per ml, subtype adr or ayw, were treated with either 1 microgram/ml pepsin at pH 2.0 for 18 hours, 8 M urea for four hours, or 1:4,000 formalin for 72 hours. One ml of the serum containing hepatitis B virus subjected to each of the procedures was inoculated intravenously into one or two susceptible chimpanzees (total of eight chimpanzees). No evidence of hepatitis B infection was detected in weekly serum samples from the chimpanzees during six months of observation. These three procedures are currently applied during manufacture to inactivate HBV which might be present in the hepatitis B vaccine licensed in the United States. The data from this study combined with data documenting that the physical purification of the vaccine is capable of removing hepatitis B virus provide assurance that there is no residual live hepatitis B virus in the vaccine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6403664     DOI: 10.1002/jmv.1890110102

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  7 in total

Review 1.  The chimpanzee model for hepatitis B virus infection.

Authors:  Stefan F Wieland
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

2.  New hepatitis B vaccines.

Authors:  A J Zuckerman
Journal:  Br Med J (Clin Res Ed)       Date:  1985-02-16

Review 3.  Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives.

Authors:  Wolfram H Gerlich
Journal:  Med Microbiol Immunol       Date:  2014-12-19       Impact factor: 3.402

4.  Translation products of pre-S(1), pre-S(2) regions and the S gene of hepatitis B virus: susceptibility of their antigenic activities to treatment with heat, urea, formalin or pepsin.

Authors:  H Ohnuma; A Machida; E Takai; F Tsuda; H Miyamoto; T Tanaka; K Oda; S Usuda; T Nakamura; Y Miyakawa
Journal:  Clin Exp Immunol       Date:  1986-12       Impact factor: 4.330

5.  Polymerized Albumin Receptor of Hepatitis B Virus for Evading the Reticuloendothelial System.

Authors:  Kurumi Takagi; Masaharu Somiya; Joohee Jung; Masumi Iijima; Shun'ichi Kuroda
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-25

6.  Inactivation of 12 viruses by heating steps applied during manufacture of a hepatitis B vaccine.

Authors:  P N Lelie; H W Reesink; C J Lucas
Journal:  J Med Virol       Date:  1987-11       Impact factor: 2.327

Review 7.  [Hepatitis B vaccines-history, achievements, challenges, and perspectives].

Authors:  Wolfram H Gerlich
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2022-01-11       Impact factor: 1.513

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.